Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.61 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16242402 | 0.98 | EPHX2 (0.58) | EPHX2PARP10TRPA1HPGDALDH1A1 | |
| SCHEMBL17123795 | 0.93 | EPHX2 (0.54) | EPHX2PARP10TRPA1ALDH1A1TSHR | |
| SCHEMBL9572108 | 0.89 | EPHX2 (0.57) | EPHX2PARP10ADRB2FAAH | |
| SCHEMBL30045 | 0.89 | EPHX2 (0.57) | EPHX2PARP10ADRB2FAAH | |
| SCHEMBL9572112 | 0.89 | EPHX2 (0.57) | EPHX2PARP10ADRB2FAAH | |
| SCHEMBL2242868 | 0.89 | PARP10 (0.55) | EPHX2PARP10HPGDALDH1A1TSHR | |
| SCHEMBL5722140 | 0.85 | EPHX2 (0.47) | EPHX2PARP10TRPA1ADRB2FAAH | |
| SCHEMBL19838848 | 0.81 | HRH1 (0.58) | EPHX2HRH3 | |
| SCHEMBL26012610 | 0.80 | PARP10 (0.53) | EPHX2PARP10HPGDALDH1A1TSHR | |
| SCHEMBL623629 | 0.80 | PARP10 (0.53) | EPHX2PARP10HPGDALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5032971-A | — | — | None | — | — | JP | disclosed |
| US-20170327457-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-16 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| JP-H0532971-A | NEMATIC LIQUID CRYSTAL COMPOSITION | DAINIPPON INK & CHEM INC | 1993-02-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | EPHX2 1144/4885PARP10 1539/4885TRPA1 3697/4885 |
| US-20170327457-A1 | PHENYL-(AZA)CYCLOALKYL CARBOXYLIC ACID GPR120 MODULATORS | GPR88, GPR55, GPR180 | EPHX2 2672/4885PARP10 950/4885TRPA1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.